Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma

CONCLUSIONS: The 6-month disease control rate did not exceed the predefined threshold, but YS110 revealed modest efficacy in response rate as salvage therapy in difficult-to-treat patients with MPM. YS110 was generally well tolerated.PMID:34590026 | PMC:PMC8474437 | DOI:10.1016/j.jtocrr.2021.100178

Source: Clinical Lung Cancer - September 30, 2021 Category: Cancer & Oncology Authors: Kazuhiko Nakagawa Takashi Kijima Morihito Okada Masahiro Morise Motoyasu Kato Katsuya Hirano Nobukazu Fujimoto Mitsuhiro Takenoyama Hiroshi Yokouchi Yuichiro Ohe Toyoaki Hida Keisuke Aoe Takumi Kishimoto Masato Hirokawa Hironori Matsuki Yutaro Kaneko Take Source Type: research